Pacira BioSciences, Inc.
PCRXNASDAQHealthcare● Active
$22.86
+$0.11(+0.48%)
Market Cap$899198100
P/E Ratio—
52W High$27.64
52W Low$18.8
Pacira BioSciences, Inc.（PCRX）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · PCRX · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.01B | ($0.10B) | $0.04B | $0.02B | $0.04B |
| Depreciation & Amort. | $0.09B | $0.08B | $0.08B | $0.09B | $0.03B |
| Stock-Based Comp. | $0.06B | $0.05B | $0.05B | $0.05B | $0.04B |
| Change in Working Capital | ($0.04B) | ($0.02B) | ($0.05B) | ($0.02B) | ($0.02B) |
| Net Cash from Operations | $0.15B | $0.19B | $0.15B | $0.15B | $0.13B |
| Investing Activities | |||||
| Capital Expenditure | ($0.02B) | ($0.01B) | ($0.02B) | ($0.03B) | ($0.05B) |
| Purchases of Investments | ($0.14B) | ($0.25B) | ($0.14B) | ($0.40B) | ($0.63B) |
| Sales of Investments | $0.27B | $0.18B | $0.24B | $0.24B | $1.08B |
| Net Cash from Investing | $0.10B | ($0.08B) | $0.08B | ($0.23B) | ($0.02B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.15B) | ($0.03B) | ($0.00B) | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.22B) | $0.08B | ($0.18B) | ($0.43B) | $0.36B |
| Net Cash from Financing | ($0.37B) | $0.02B | ($0.18B) | ($0.40B) | $0.38B |
| Free Cash Flow | |||||
| Free Cash Flow | $0.14B | $0.18B | $0.14B | $0.12B | $0.08B |
| FCF Margin %(computed) | 18.81% | 25.50% | 20.67% | 17.28% | 14.75% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Pacira BioSciences, Inc.
关于Pacira BioSciences, Inc.（PCRX）现金流量表
Pacira BioSciences, Inc. 2025财年经营活动现金流$0.15B，自由现金流$0.14B（FCF利润率18.81%），资本支出($0.02B)。
常见问题
PCRX · 4 问Pacira BioSciences, Inc. 2025财年自由现金流$0.14B，同比down23.5%。
PCRX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10